Rani Therapeutics (RANI) Competitors $0.53 0.00 (-0.56%) Closing price 04:00 PM EasternExtended Trading$0.54 +0.01 (+1.52%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RANI vs. GNLX, CGEN, KRRO, SPRO, BHST, FATE, MCRB, IMRX, PLX, and IKTShould you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Genelux (GNLX), Compugen (CGEN), Korro Bio (KRRO), Spero Therapeutics (SPRO), BioHarvest Sciences (BHST), Fate Therapeutics (FATE), Seres Therapeutics (MCRB), Immuneering (IMRX), Protalix BioTherapeutics (PLX), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Rani Therapeutics vs. Its Competitors Genelux Compugen Korro Bio Spero Therapeutics BioHarvest Sciences Fate Therapeutics Seres Therapeutics Immuneering Protalix BioTherapeutics Inhibikase Therapeutics Rani Therapeutics (NASDAQ:RANI) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability. Does the media refer more to RANI or GNLX? In the previous week, Rani Therapeutics had 1 more articles in the media than Genelux. MarketBeat recorded 6 mentions for Rani Therapeutics and 5 mentions for Genelux. Genelux's average media sentiment score of 1.38 beat Rani Therapeutics' score of 0.92 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RANI or GNLX more profitable? Genelux's return on equity of -107.47% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rani TherapeuticsN/A -2,272.39% -97.97% Genelux N/A -107.47%-83.14% Which has higher earnings & valuation, RANI or GNLX? Genelux has lower revenue, but higher earnings than Rani Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRani Therapeutics$1.03M32.40-$30.02M-$0.91-0.58Genelux$10K12,086.40-$29.87M-$0.86-3.72 Do analysts prefer RANI or GNLX? Rani Therapeutics currently has a consensus price target of $7.33, suggesting a potential upside of 1,288.89%. Genelux has a consensus price target of $17.75, suggesting a potential upside of 454.69%. Given Rani Therapeutics' higher probable upside, research analysts plainly believe Rani Therapeutics is more favorable than Genelux.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more risk & volatility, RANI or GNLX? Rani Therapeutics has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Comparatively, Genelux has a beta of -0.32, suggesting that its share price is 132% less volatile than the S&P 500. Do institutionals & insiders hold more shares of RANI or GNLX? 30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 45.1% of Rani Therapeutics shares are held by company insiders. Comparatively, 8.8% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryGenelux beats Rani Therapeutics on 10 of the 16 factors compared between the two stocks. Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RANI vs. The Competition Export to ExcelMetricRani TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.56M$3.04B$5.55B$9.83BDividend YieldN/A2.27%4.62%4.11%P/E Ratio-0.5820.6730.1526.03Price / Sales32.40367.61462.89105.43Price / CashN/A42.0537.7558.93Price / Book-3.777.638.476.06Net Income-$30.02M-$54.65M$3.26B$265.11M7 Day Performance-3.95%3.95%3.56%2.90%1 Month Performance-18.01%11.46%5.97%3.99%1 Year Performance-80.44%13.04%42.70%26.92% Rani Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RANIRani Therapeutics2.5414 of 5 stars$0.53-0.6%$7.33+1,288.9%-78.3%$33.56M$1.03M-0.58110News CoverageEarnings ReportGNLXGenelux1.6686 of 5 stars$3.51flat$17.75+405.7%+60.3%$132.54M$10K-3.9910Earnings ReportGap UpCGENCompugen1.9363 of 5 stars$1.46-1.4%$4.00+174.0%-12.0%$132.07M$27.86M-9.1370Earnings ReportAnalyst RevisionKRROKorro Bio1.186 of 5 stars$15.49+11.8%$102.43+561.3%-55.5%$130.06M$2.27M-1.6470News CoverageEarnings ReportAnalyst ForecastSPROSpero Therapeutics4.2648 of 5 stars$2.26-1.7%$5.00+121.2%+82.9%$128.59M$47.98M-1.77150News CoverageEarnings ReportBHSTBioHarvest SciencesN/A$7.67-0.3%$13.67+78.2%N/A$126.28M$27.70M-15.34N/ANews CoverageEarnings ReportFATEFate Therapeutics4.1618 of 5 stars$1.06-0.9%$3.83+261.6%-71.9%$122.63M$13.63M-0.71550Trending NewsEarnings ReportAnalyst DowngradeMCRBSeres Therapeutics3.1898 of 5 stars$14.78+5.6%$73.67+398.4%-13.3%$122.17M$126.32M-3.21330Earnings ReportIMRXImmuneering3.5625 of 5 stars$3.43+1.8%$13.25+286.3%+185.1%$121.27MN/A-1.7560News CoverageEarnings ReportGap DownPLXProtalix BioTherapeutics3.6299 of 5 stars$1.50+3.4%$15.00+900.0%+56.2%$119.41M$59.76M-11.54200News CoverageInsider TradeIKTInhibikase Therapeutics1.9499 of 5 stars$1.60+5.3%$6.50+306.3%+32.6%$118.95MN/A-0.606 Related Companies and Tools Related Companies GNLX Alternatives CGEN Alternatives KRRO Alternatives SPRO Alternatives BHST Alternatives FATE Alternatives MCRB Alternatives IMRX Alternatives PLX Alternatives IKT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RANI) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access